Orexin pathway modulation in narcolepsy: from Autoimmune mechanisms to nanotechnology enabled therapeutic delivery.

Narcolepsy is a long-term brain disorder caused by disrupted orexin signaling. Orexin neurons sit in the hypothalamus and control the sleep-wake cycle; damage to these neurons leads to narcolepsy. Early evidence pointed to an autoimmune attack on orexin neurons as the main cause. Current treatments - stimulants, antidepressants, sodium oxybate, and scheduled naps - ease symptoms but do not stop the disease, and they often cause side effects such as anxiety, insomnia, and heart problems. Most of these drugs also cannot cross the blood-brain barrier (BBB) to act directly on the hypothalamus. This review examines the autoimmune basis of orexin neuron loss in narcolepsy and looks at how nanotechnology-based delivery systems could carry orexin peptides, genes, or antibodies across the BBB. We highlight priorities for future work: nano-enabled drug delivery, gene and peptide-based therapies, long-term safety data, and treatment approaches tailored to each patient. Progress in this area could shift narcolepsy care from symptom control toward real disease-modifying therapy.